✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Triapine is an investigational drug.
There have been 32 clinical trials for Triapine. The most recent clinical trial was a Phase 2 trial, which was initiated on January 15th 2016.
The most common disease conditions in clinical trials are Adenocarcinoma, Leukemia, and Vaginal Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Vion Pharmaceuticals, and NRG Oncology.
There are three hundred and eighty US patents protecting this investigational drug and four international patents.
Recent Clinical Trials for Triapine
|Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy||National Cancer Institute (NCI)||Early Phase 1|
|Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors||National Cancer Institute (NCI)||Phase 1|
|Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer||National Cancer Institute (NCI)||Phase 1|
Top disease conditions for Triapine
Top clinical trial sponsors for Triapine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Triapine||See Plans and Pricing||Methods and compositions for inhibition of Ras||ARAXES PHARMA LLC (San Diego, CA)||See Plans and Pricing|
|Triapine||See Plans and Pricing||Treatment of solid tumours||VIVOLUX AB (Uppsala, SE)||See Plans and Pricing|
|Triapine||See Plans and Pricing||Polynucleotides encoding immune modulating polypeptides||ModernaTX, Inc. (Cambridge, MA)||See Plans and Pricing|
|Triapine||See Plans and Pricing||Substituted imidazo[1,5-a]pyrazines as Btk inhibitors||Merck Sharp & Dohme Corp. (Rahway, NJ)||See Plans and Pricing|
|Triapine||See Plans and Pricing||Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid||MERCK & CIE (Schaffhausen, CH)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Triapine||World Intellectual Property Organization (WIPO)||WO2016049568||2034-09-25||See Plans and Pricing|
|Triapine||Australia||AU2012231814||2031-03-21||See Plans and Pricing|
|Triapine||Brazil||BR112013024211||2031-03-21||See Plans and Pricing|
|Triapine||Canada||CA2830081||2031-03-21||See Plans and Pricing|
|Triapine||China||CN103547268||2031-03-21||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|